Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Non Operating Investment Income (2018 - 2025)

Lexaria Bioscience's Non Operating Investment Income history spans 8 years, with the latest figure at -$22093.0 for Q4 2025.

  • For Q4 2025, Non Operating Investment Income fell 38.67% year-over-year to -$22093.0; the TTM value through Nov 2025 reached -$39875.0, down 22.5%, while the annual FY2025 figure was -$33714.0, 51.72% up from the prior year.
  • Non Operating Investment Income for Q4 2025 was -$22093.0 at Lexaria Bioscience, down from -$11447.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $34040.0 in Q1 2025 and bottomed at -$143918.0 in Q3 2023.
  • The 5-year median for Non Operating Investment Income is -$19012.5 (2024), against an average of -$27764.1.
  • The largest annual shift saw Non Operating Investment Income tumbled 4307.73% in 2021 before it soared 862.51% in 2024.
  • A 5-year view of Non Operating Investment Income shows it stood at -$41362.0 in 2021, then plummeted by 87.68% to -$77628.0 in 2022, then surged by 31.45% to -$53215.0 in 2023, then soared by 70.06% to -$15932.0 in 2024, then crashed by 38.67% to -$22093.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Non Operating Investment Income are -$22093.0 (Q4 2025), -$11447.0 (Q3 2025), and -$40375.0 (Q2 2025).